Introduction:
Dealing with cancer is tough and taxing, and so are its therapeutic modalities. There are several interventional strategies that are being advocated for cancer patients. However, the type and form of interventional modalities are largely mastered and governed by cancer type and its progression phase. In cancer, the cells that are otherwise highly regulated lose their intrinsic attributes and traits and haphazardly propagate aimlessly, bringing up cellular gatherings and agglomerations. Such cancer cells are resistant and defiant to natural cell death. Instead, they hold on like immortal cells. This attribute further upscales and expedites cellular assemblage and cancer advancement. In later stages, there is an augmented inclination for the cancer cells to disseminate and drift into other vital structures, gravitating to the graveness of the ailment.
What Is Blood Cancer?
Cancer that emerges and evolves from blood cells, among white blood cells, platelets, red blood cells, or other cellular entities in the blood plasma, is quoted as blood cancer. Blood cancers invoke derangements in the blood cell proportions, their functions, and even their structure. Blood cancer could also emerge from cancers that root from the blood cells’ progenitors (hematopoietic stem cells), which directly hamper and shackle blood cell production.
What Is Photodynamic Therapy?
Photodynamic therapy is a discrete and highly efficacious interventional modality framed to counter various cancer forms. Photodynamic therapy is quite familiar and is known by other denominations as photo radiation therapy or photochemotherapy. In photodynamic therapy, otherwise called PDT, certain medicated agents and drugs are instituted. These drug forms that are advocated in photodynamic therapy are labeled as photosensitizing agents. Photosensitizing agents, as such, do not express any therapeutic potential owing to their inert phase, which calls for an external triggering agent to turn it on.
Alongside the photosensitizing agent, photodynamic therapy employs light waves to counter and mutilate the cancer cells. It is these light waves that could turn on or catalyze the drug entity called photosensitizing agents. Only when the photosensitizing agents are triggered and energized by the light beam are their therapeutic attributes brought out and projected, which enables and enhances their capabilities and attributes to inflict harm to cancer cells. The route or channel through which photosensitizing agents are to be instituted is guided by the area to be medicated and treated.
The photosensitizing agents could be instilled into the body through the bloodstream, limited to skin exposure, or delivered orally. Once the photosensitizing agents are instilled through the aptest implement, a notable proportion of these agents are uptaken by cancer cells, and they assimilate within those cancer cells. The light exposure is held up and detained for a specific period, which warrants sufficient photosensitizing agents’ assimilation within cancer cells, while the photosensitizing agent clears off and drops down its proportions in healthy cells. This time-lapse across photosensitizer instillation and its light-mediated triggering is quoted as the “drug-to-light interval,” which typically ranges from 24 to 72 hours. The light waves strike and trigger the photosensitive agent, turning them on and functional. Thus, triggered photosensitizing agents yield and give off reactive oxygen entities, otherwise called oxygen radicals, that could invoke and inflict total mutilation and defacement of the cancer cells.
How Does Photodynamic Therapy Work for Blood Cancer Patients?
Photodynamic therapy underscores the recovery prospects of blood cancers. Owing to different blood cell subsets, blood cancers could also be of different listings or genres. In all these cases, photodynamic therapy stamps out cancer cell proportions in the blood while excusing healthy blood cells that accompany and coexist with cancer cells. The technicalities implicated with photodynamic therapy are also revised to accommodate the need for each of the blood cancer subsets.
Extracorporeal photopheresis is one such revised photodynamic therapy that has been implemented, and it advocates for a specific blood cancer variant called cutaneous T cell lymphoma. In extracorporeal photopheresis, unlike conventional photodynamic therapy, the patient’s blood is channeled to an external machine-operated device, wherein the lymphocytes (white blood cell type) are segregated from other blood cells. Photosensitizers are then instilled into the segregated lymphocytes. The machine design accommodates an inherent ultraviolet A (UV A) light source. The segregated lymphocytes are thus made susceptible to the light (UV A) rays within the machine. These rays trigger off and energize the photosensitizer, thus inflicting refinement and revisions in lymphocytes to gravitate its defense to clear off cancer cells, mitigating its aberrant behavior. The segregated and treated lymphocytes are then brought back to the body along with the remaining blood components.
Photodynamic therapy is also instituted to gravitate and complement other interventional modalities advocated for blood cancers. Autologous hematopoietic stem cells (blood cell progenitors) transplantation is employed in blood cancer patients, where the patient's own hematopoietic stem cells are withdrawn and garnered ahead of cancer therapies (radiation or chemotherapy), which are later transplanted to reinstate the healthy blood cell proportions. Cancer therapies could mutilate the stem cells' vitality and subjugate this autologous hematopoietic stem cell transplantations are instituted. However, the scope for carcinogenic transfiguration among the garnered stem cells could not be excluded. Photodynamic therapy is instituted to eradicate and decimate cancer cells within the intended transplant specimen. However, unlike conventional PDT, the therapy is executed in laboratory settings. The withdrawn stem cells are exposed to PDT to efface and wipe out cancer cells from the specimen. This strategy upscales the transplant purity while downgrading the proclivity for relapses.
What Are the Other Medical Conditions for Which Photodynamic Therapy Could Be Advocated?
Photodynamic therapy is employed for different cancer forms, ranging from blood cancers, lung cancer (cancer rooted in the lung tissue), skin cancer (cancer erupting from the skin cells) to brain cancer (cancer inflicted upon the brain cells). In addition to the cancers, photodynamic therapy could also be instituted for several other non-cancerous ailments. A few of the non-cancerous comorbidities for which photodynamic therapy could be advocated include the following:
-
Psoriasis (skin condition inflicted by overstated immune response).
-
Acute sinusitis (sinus infection).
-
Vitiligo (elicited as abnormally whitened skin patches).
-
Urinary tract infections.
-
Oral infections.
-
Actinic keratosis (roughened and flaky skin).
-
Corneal infection (an eye infection).
-
Gastritis (gut lining cells swell up).
Conclusion:
Photodynamic therapy is recognized to be a potent therapeutic strategy for blood cancers, with minimal toxicity attributes. It could either be instituted as the mainstay therapy or could be teamed with other cancer therapies to augment the recovery prospects, enabling flexible treatment plans. Selective targeting attributes of PDT underscore its potentiality in excusing noncancerous healthy cells. Further investigations are on their way to explore more of its therapeutic attributes.
